Topic: BIOGEN
36 results were found.
Keppel partners AM Green to explore biogenic carbon based sustainable fuels opportunities in Asia and Middle East - December 11, 2023
Biogen to acquire Reata for approximately $7.3bn - August 3, 2023
Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen - February 2, 2023
Biogen to pay $900 million to settle allegations related to improper physician payments - September 28, 2022
Biogen to pay $22 million to resolve U.S. drug charity kickback probe - December 18, 2020
Biogen to acquire clinical stage psychiatric and neurological drug from Pfizer for maybe $635m - January 14, 2020
Biogen profit rises 72% - July 23, 2019
Biogen completes acquisition of Nightstar Therapeutics for approximately $800 million - June 7, 2019
Biogen Q1 adjusted earnings beat estimates comparing to last year - April 24, 2019
Fujifilm to buy Biogen Danish subsidiary for $890 million - March 12, 2019
Biogen to buy Nightstar Therapeutics in $800 million deal - March 4, 2019
Biogen Q2 total revenues $3.1 billion - July 25, 2017
Biogen appoints Anirvan Ghosh as SVP - March 17, 2017
Biogen to pay $1.25bn for license agreement to Forward Pharma - January 17, 2017
Biogen appoints Michel Vounatsos as CEO - December 20, 2016
Biogen names two new executives for Bioverativ spinoff - November 16, 2016
Biogen Q2 total revenues increased 12% - July 21, 2016
Biogen names EVP, pharmaceutical operations & technology - June 22, 2016
Biogen plans to spin off its hemophilia business - May 3, 2016
Biogen appoints Michael Ehlers EVP, research and development - April 28, 2016
Biogen Q1 2016 total revenues $2.7 billion - April 22, 2016
Biogen names Michel Vounatsos EVP, chief commercial officer - March 31, 2016
Biogen vice president Tony Kingsley to leave - October 12, 2015
Biogen Q2 revenues of $2.6 billion, 7% better - July 24, 2015
EVP Douglas E. Williams to leave Biogen - July 13, 2015
Biogen announces $5 billion share repurchase - May 8, 2015
Biogen Q1 revenues increased 20 percent - April 27, 2015
Biogen Idec 2014 revenues increase 40% to $9.7 billion - January 31, 2015
Biogen Idec to buy Convergence Pharmaceuticals of UK for up to $675m - January 14, 2015
Biogen Idec names EVP, technology and business solutions - August 27, 2014
Biogen Idec names chief strategy officer - April 11, 2014
Biogen Idec chairman William D. Young to step down - February 18, 2014
Biogen Idec appoints Eric Rowinsky and Stephen Sherwin to board of directors - March 25, 2010
Med BioGene appoints Michael R. Hayden as director - January 18, 2010
Biogen Idec appoints three senior executives - January 8, 2010
Biogen Idec: CEO James C. Mullen to retire - January 5, 2010